These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Clinical Development of Anti-mitotic Drugs in Cancer. Olziersky AM; Labidi-Galy SI Adv Exp Med Biol; 2017; 1002():125-152. PubMed ID: 28600785 [TBL] [Abstract][Full Text] [Related]
5. Mitosis is not a key target of microtubule agents in patient tumors. Komlodi-Pasztor E; Sackett D; Wilkerson J; Fojo T Nat Rev Clin Oncol; 2011 Feb; 8(4):244-50. PubMed ID: 21283127 [TBL] [Abstract][Full Text] [Related]
6. Role of prolonged mitotic checkpoint activation in the formation and treatment of cancer. Dalton WB; Yang VW Future Oncol; 2009 Nov; 5(9):1363-70. PubMed ID: 19903065 [TBL] [Abstract][Full Text] [Related]
7. Inhibitors targeting mitosis: tales of how great drugs against a promising target were brought down by a flawed rationale. Komlodi-Pasztor E; Sackett DL; Fojo AT Clin Cancer Res; 2012 Jan; 18(1):51-63. PubMed ID: 22215906 [TBL] [Abstract][Full Text] [Related]
8. Too early to say, "no targeting of mitosis!". Kitagawa K Nat Rev Clin Oncol; 2011 May; 8(7):444; author reply 444. PubMed ID: 21587220 [No Abstract] [Full Text] [Related]
9. An update on the developing mitotic inhibitors for the treatment of non-small cell carcinoma. Sacco PC; Gridelli C Expert Opin Emerg Drugs; 2017 Sep; 22(3):213-222. PubMed ID: 28836854 [TBL] [Abstract][Full Text] [Related]
12. Tales of how great drugs were brought down by a flawed rationale--letter. Wissing MD; Carducci MA; Gelderblom H; van Diest PJ Clin Cancer Res; 2013 Mar; 19(5):1303. PubMed ID: 23393074 [No Abstract] [Full Text] [Related]
13. Tales of how great drugs were brought down by a flawed rationale--letter. Tunquist BJ; Wood KW; Walker DH Clin Cancer Res; 2013 Mar; 19(5):1302. PubMed ID: 23393075 [No Abstract] [Full Text] [Related]
14. Tales of how great drugs were brought down by a flawed rationale--response. Komlodi-Pasztor E; Sackett DL; Fojo T Clin Cancer Res; 2013 Mar; 19(5):1304. PubMed ID: 23393076 [No Abstract] [Full Text] [Related]
15. Regulation of cancer cell survival by BCL2 family members upon prolonged mitotic arrest: opportunities for anticancer therapy. Barillé-Nion S; Bah N; Véquaud E; Juin P Anticancer Res; 2012 Oct; 32(10):4225-33. PubMed ID: 23060542 [TBL] [Abstract][Full Text] [Related]
16. Targeting mitosis for anti-cancer therapy. Sudakin V; Yen TJ BioDrugs; 2007; 21(4):225-33. PubMed ID: 17628120 [TBL] [Abstract][Full Text] [Related]
17. Mitotic drug targets and the development of novel anti-mitotic anticancer drugs. Schmidt M; Bastians H Drug Resist Updat; 2007; 10(4-5):162-81. PubMed ID: 17669681 [TBL] [Abstract][Full Text] [Related]
18. Consequences of mitotic slippage for antimicrotubule drug therapy. Cheng B; Crasta K Endocr Relat Cancer; 2017 Sep; 24(9):T97-T106. PubMed ID: 28684541 [TBL] [Abstract][Full Text] [Related]
19. Targeting mitotic pathways for endocrine-related cancer therapeutics. Agarwal S; Varma D Endocr Relat Cancer; 2017 Sep; 24(9):T65-T82. PubMed ID: 28615236 [TBL] [Abstract][Full Text] [Related]
20. Polo-like kinase 1 inhibitor BI2536 causes mitotic catastrophe following activation of the spindle assembly checkpoint in non-small cell lung cancer cells. Choi M; Kim W; Cheon MG; Lee CW; Kim JE Cancer Lett; 2015 Feb; 357(2):591-601. PubMed ID: 25524551 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]